HS1 - L24 Pharmacology and Functional Organisation of the Sympathetic Nervous System
Functional Organisation of the Nervous System
- The nervous system is divided into two primary structural components:
- Central Nervous System (CNS): Consists of the brain and the spinal cord.
- Peripheral Nervous System (PNS): Consists of the cranial and spinal nerves.
- The nervous system is further categorized into functional divisions:
- Motor Division (Efferent): Transmits signals from the CNS to effector organs.
- Sensory Division (Afferent): Transmits signals from sensory receptors to the CNS.
- The Motor Division contains two main systems:
- Somatic Nervous System: Responsible for voluntary control of skeletal muscles.
- Autonomic Nervous System (ANS): Responsible for involuntary control of internal organs and glands.
- The Autonomic Nervous System is subdivided into:
- Sympathetic Nervous System
- Parasympathetic Nervous System
- Enteric Nervous System: Manages the gastrointestinal tract and can operate independently of the CNS.
Anatomical Projections and Ganglia
- Sympathetic Nervous System Projections:
- Projections originate from the Cervical, Thoracic, and Lumbar regions of the spinal cord.
- Major ganglia involved include the Superior cervical ganglion, Stellate ganglion, Paravertebral chain, Celiac ganglion, Superior mesenteric ganglion, and Inferior mesenteric ganglion.
- The Splanchnic nerve delivers signals to various abdominal organs.
- The Adrenal medulla receives direct sympathetic innervation.
- Parasympathetic Nervous System Projections:
- Projections originate from the Midbrain, Pons, Medulla, and the Sacral region of the spinal cord.
- Key cranial nerves for the parasympathetic system include:
- Oculomotor nerve (III): Projects to the eye.
- Facial nerve (VII) and Glossopharyngeal nerve (IX): Project to the lacrimal and salivary glands.
- Vagus nerve (X): Provides extensive innervation to the lungs, heart, liver, stomach, pancreas, small intestine, and large intestine/rectum.
- The Sacral region provides innervation to the bladder and reproductive organs.
Physiological Effects of Autonomic Stimulation
- Eye (Iris):
- Sympathetic: Pupil dilation.
- Parasympathetic: Pupil constriction.
- Salivary Glands:
- Sympathetic: Reduced production of saliva.
- Parasympathetic: Increased production of saliva.
- Oral and Nasal Mucosa:
- Sympathetic: Reduced mucus production.
- Parasympathetic: Increased mucus production.
- Heart:
- Sympathetic: Increased heart rate and increased force of contraction.
- Parasympathetic: Decreased heart rate and decreased force of contraction.
- Lungs:
- Sympathetic: Relaxation of bronchial muscle (bronchodilation).
- Parasympathetic: Contraction of bronchial muscle (bronchoconstriction).
- Stomach:
- Sympathetic: Reduced peristalsis.
- Parasympathetic: Increased motility and secretion of gastric juice.
- Small Intestine:
- Sympathetic: Reduced motility.
- Parasympathetic: Increased digestion activities.
- Large Intestine:
- Sympathetic: Reduced motility.
- Parasympathetic: Increased secretions and motility.
- Liver:
- Sympathetic: Increased conversion of glycogen to glucose.
- Kidney:
- Sympathetic: Decreased urine secretion.
- Parasympathetic: Increased urine secretion.
- Adrenal Medulla:
- Sympathetic: Secretion of norepinephrine and epinephrine.
- Bladder:
- Sympathetic: The bladder wall is relaxed and the sphincter is closed.
- Parasympathetic: The bladder wall is contracted and the sphincter is relaxed.
Chemical Transmission and Synaptic Organisation
- Parasympathetic Pathway: Signals travel from the CNS to a ganglion via Acetylcholine (ACh) acting on Nicotinic (n) receptors. From the ganglion, the signal moves to the effector organ via ACh acting on Muscarinic (m) receptors.
- Sympathetic Pathway (Standard): Signals travel from the CNS to a ganglion via ACh acting on Nicotinic receptors. From the ganglion, the signal moves to the effector organ via Noradrenaline (NAd/Norepinephrine).
- Sympathetic Pathway (Adrenal): Signals travel from the CNS via ACh acting on Nicotinic receptors in the Adrenal medulla, which then releases Adrenaline (Ad/Epinephrine) and some NAd directly into the bloodstream.
- Cholinergic Transmission Specifics:
- The synapse between all preganglionic sympathetic and parasympathetic neurons involves the release of ACh onto neuronal nicotinic receptors (nAChRs).
- Neuronal nAChRs consist of α2−7 subunits, most commonly configured as (α3)2(β4)3.
- The nAChR is an ion channel that allows the influx of Na+ when two molecules of ACh bind to the extracellular domain.
- Hexamethonium:
- This is a selective antagonist for the neuronal sub-type of nicotinic receptors.
- It is not a competitive antagonist.
- It effectively blocks all effects resulting from autonomic stimulation.
Adrenoceptors: Classification and Function
- Adrenoceptors are the key receptors responding to noradrenaline released from sympathetic terminals and circulating noradrenaline.
- All adrenoceptors are G-protein coupled receptors (GPCRs) containing seven transmembrane domains, an extracellular ligand-binding domain, and an intracellular G-protein coupling domain.
- Sub-type Specificity:
- α1: Responsible for smooth muscle contraction (e.g., vasoconstriction).
- α2: Involved in vasoconstriction and acts as a pre-synaptic receptor for feedback inhibition.
- β1: Increases heart rate and contractility.
- β2: Responsible for smooth muscle relaxation (e.g., bronchodilation and vasodilation).
- β3: Causes relaxation of the bladder smooth muscle and stimulates lipolysis.
G-Protein Signaling Mechanism
- The Signaling Cycle:
- In the inactive state, the receptor is associated with a G protein complex (α,β,γ subunits) bound to GDP.
- Upon ligand (noradrenaline) binding, GTP replaces GDP on the α subunit.
- The activated G protein interacts with a target protein in the plasma membrane (e.g., an enzyme or ion channel) to produce a cellular effect.
- α1 Adrenoceptor Coupling:
- The α1 receptor is coupled to the Gq protein.
- The Gq protein activates Phospholipase C-β (PLC).
- PLC converts membrane phosphoinositides into Inositol trisphosphate (IP3) and Diacylglycerol (DAG).
- IP3 binds to IP3 receptors on the endoplasmic reticulum, facilitating the release of intracellular Calcium (Ca2+).
- The resulting increase in Ca2+ concentration produces the physiological effect (e.g., contraction).
Pharmacological Applications of Sympathetic Agents
- α-Receptor Agonists:
- Vasoconstrictors with local anaesthetics: Adrenaline and Noradrenaline (primarily acting on α1).
- Nasal Decongestants: Phenylephrine (primarily α1).
- Hypertension Treatment: Clonidine, which acts on central α2 receptors.
- β-Receptor Agonists:
- Cardiogenic Shock: Adrenaline and Dobutamine (acting on β1).
- Anaphylactic Shock: Adrenaline (mixed α/β agonist action).
- Asthma: Salbutamol (selective β2 agonist); also used to delay premature labour.
- α-Antagonists:
- Hypertension: Doxazosin (selective α1 antagonist).
- Benign Prostatic Hyperplasia: Tamsulosin (selective α1 antagonist).
- β-Antagonists (Beta-blockers):
- Examples include Propranolol (non-selective β1/β2) and Metoprolol (selective β1).
- Indications: Angina, cardiac arrhythmias, hypertension, anxiety states, and chronic heart failure.
- Glaucoma: Timolol is used locally.
- Synthesis Pathway:
- Tyrosine is converted into Dihydroxyphenylalanine (DOPA).
- DOPA is converted into Dopamine.
- Dopamine is transported into storage vesicles by the Vesicular Monoamine Transporter (VMAT).
- Inside the vesicle, dopamine is converted into Noradrenaline (NAd).
- Degradation Enzymes:
- Monoamine Oxidase (MAO): Breaks down catecholamines within the nerve terminal (mitochondria).
- Catechol-O-methyltransferase (COMT): Breaks down catecholamines in muscle cells or other effector cell types.
Termination of Noradrenaline Action: Uptake 1
- Mechanism of Uptake 1:
- This is the primary mechanism for terminating the actions of NAd in the synapse using the Norepinephrine Transporter (NET).
- It is a secondary active transporter that cotransports Na+, Cl−, and the catecholamine.
- Properties: High affinity for noradrenaline but a low maximal rate of uptake. It is relatively selective (NAd>Ad>isoprenaline).
- Inhibitors of NET:
- Inhibitors include cocaine, tricyclic antidepressants (such as desipramine), and phenoxybenzamine.
- NET is closely related to transporters for dopamine (DAT) and serotonin (SERT).
- Inhibitory Effects:
- Desipramine: A tricyclic antidepressant used primarily in the CNS. Adverse effects include tachycardia and dysrhythmia.
- Cocaine: Acts as a local anaesthetic but also causes euphoria and excitement (CNS) and tachycardia/increased blood pressure (Peripheral).
Mono-amine Oxidase Inhibitors (MAOIs)
- Most MAOIs block the enzyme irreversibly.
- They are used clinically as antidepressants to increase brain and peripheral levels of noradrenaline, dopamine, and 5-HT.
- Adverse Effects: Postural hypotension, weight gain, restlessness, and insomnia.
- Cheese Reaction: A hypertensive episode characterized by flushing that occurs when a patient on MAOIs consumes tyramine-containing food (e.g., cheese).
- Examples: Phenelzine, tranylcypromine, and iproniazid are irreversible inhibitors; Moclobemide is a reversible, competitive inhibitor.
Indirectly Acting Sympathetic Amines
- Examples include Amfetamine, ephedrine, and tyramine.
- These compounds are structurally related to noradrenaline and utilize the NET for transport into the nerve terminal and vesicles.
- Action Mechanism: They displace endogenous noradrenaline from vesicles. The noradrenaline then leaks out into the synapse via the NET.
- They produce similar effects on dopamine and 5-HT in the CNS.
- Physiological Effects: Mimic noradrenaline's long-lasting effects, including bronchodilatation, vasoconstriction, positive inotropy, and raised blood pressure.
- Their CNS effects contribute to their potential as substances of abuse.
Physiological Dimensions of Sympathetic Nerves
- Postganglionic sympathetic nerves vary in length from 1cm up to 1m.
- The axon diameter is roughly 30μm.
- Varicosities on the nerve terminal have the following approximate dimensions:
- Varicosity diameter: ≈1μm.
- Individual vesicle diameter: ≈0.1μm.
- Spacing between varicosities: ≈2μm.
- Synaptic cleft width: 1.5μm to 2μm.